# Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

> **NCT03019653** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 40 (actual)

## Conditions studied

- Heart Failure
- Cardiorenal Disease
- Renal Disfunction

## Interventions

- **DRUG:** ANX-042
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03019653
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-09-13
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019653, "Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03019653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*